Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

30.34
+0.82002.78%
Pre-market: 29.72-0.6200-2.04%09:02 EDT
Volume:1.06M
Turnover:31.97M
Market Cap:3.86B
PE:-7.85
High:30.56
Open:29.89
Low:29.74
Close:29.52
52wk High:31.74
52wk Low:10.07
Shares:127.33M
Float Shares:89.84M
Volume Ratio:0.70
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:8.33
PE(LYR):-9.22

Loading ...

Mizuho Securities Sticks to Its Buy Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Jun 11

Arcus Biosciences grants new hire options for 2,850 shares, RSUs for 1,450 shares under inducement plan

Reuters
·
Jun 10

Arcus Biosciences Initiated at Outperform by LifeSci Capital

Dow Jones
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jun 04

Arcus enters clinical trial collaboration, supply agreement with Bristol Myers

TIPRANKS
·
Jun 03

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

Dow Jones
·
Jun 03

Arcus Biosciences, Bristol Myers Squibb team up to test casdatifan combo in kidney cancer trial

Reuters
·
Jun 03

Arcus Biosciences - Announces Clinical Trial Collaboration With Bristol Myers Squibb

THOMSON REUTERS
·
Jun 03

Arcus Biosciences - to Supply Casdatifan for Phase 1/2 Rosetta Rcc-208 Trial

THOMSON REUTERS
·
Jun 03

Arcus Biosciences - to Initiate Phase 3 First-Line Metastatic Ccrcc Study by Year-End 2026

THOMSON REUTERS
·
Jun 03

Arcus Biosciences - Each Company Retains Development and Commercial Rights to Their Assets

THOMSON REUTERS
·
Jun 03

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination With Pd‑L1/Vegf‑a Bispecific Immunomodulator to Treat Kidney Cancer

THOMSON REUTERS
·
Jun 03

Arcus Biosciences Chief Accounting Officer Alexander Azoy disposes of 2,562 common shares for $66,029.72

Reuters
·
Jun 02

Arcus Biosciences to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
May 27

Arcus Biosciences Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 18

Arcus Biosciences assumed with a Buy at Truist

TIPRANKS
·
May 18

U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals

Reuters
·
May 18

Arcus CFO Robert C. Goeltz II disposes 7,763 shares worth $198,913.69

Reuters
·
May 13

Arcus Biosciences Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 12

Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley

TIPRANKS
·
May 11